The identification of genetic factors influencing cardiac growth independently of increased load is crucial to an understanding of the molecular and cellular basis of pathological cardiac hypertrophy. The central aim of this investigation was to determine how pathological hypertrophy in the adult can be linked with disturbances in cardiomyocyte growth and viability in early neonatal development. The hypertrophic heart rat (HHR) model is derived from the spontaneously hypertensive rat and exhibits marked cardiac hypertrophy, in the absence of a pressure load at maturity. Hearts were harvested from male HHR, and control strain normal heart rats (NHR), at different stages of postnatal development [neonatal (P2), 4 wk, 6 wk, 8 wk, 12 wk, 20 wk]. Isolated neonatal cardiomyocytes were prepared to evaluate cell size, number, and binucleation. At postnatal day 2, HHR hearts were considerably smaller than control NHR (4.3 Ϯ 0.2 vs. 5.0 Ϯ 0.1 mg/g, P Ͻ 0.05). Cardiac growth restriction in the neonatal HHR was associated with reduced myocyte size (length and width) and an increased proportion of binucleated cardiomyocytes. Furthermore, the number of cardiomyocytes isolated from HHR neonatal hearts was significantly less (ϳ29%) than NHR. We also observe that growth stress in the neonate is associated with accentuated PI3K and suppressed MAPK activation, although these signaling pathways are normalized in the adult heart exhibiting established hypertrophy. Thus, using the HHR model, we identified novel molecular and cellular mechanisms involving premature exit from the cell cycle, reduced cardiomyocyte endowment, and dysregulated trophic signaling during early development, which are implicated in the etiology of heritable cardiac hypertrophy in the adult.
cardiac development; genetics; proliferation; apoptosis; developmental origins of adult disease; physiological and pathological cardiac hypertrophy WITH THE EXCEPTION OF AGE, cardiac hypertrophy is the most predictive cardiovascular risk factor (28) . Cardiac hypertrophy is often seen in association with hypertension, yet hypertrophy may be absent (25) or exaggerated (39) in hypertensive patients. Furthermore, therapeutic normalization of blood pressure in hypertensive patients produces only partial regression of cardiac hypertrophy (12) . In the spontaneously hypertensive rat (SHR), a genetic model of essential hypertension, which displays marked cardiac hypertrophy, it is evident that the cardiac phenotype arises only partly from the pressure workload (1, 24) . We have previously identified a genetic locus in the SHR on chromosome 2 (left ventricular mass locus 1, Lvm-1), which was significantly associated with left ventricular mass, but not blood pressure (22) . The identification of genetic factors influencing cardiac growth independently of increased load is crucial to an understanding of the molecular and cellular basis of pathological cardiac hypertrophy.
Epidemiological and experimental evidence has focused attention on early life, including the perinatal period, as a critical time during which structural and functional modeling influences have long-term consequences in relation to adult cardiovascular disease (33) . Relatively little is known about the early developmental origins of the hypertrophic heart. The heart grows rapidly during the neonatal period. In the fetus, cardiomyocyte growth is mainly hyperplastic, but when cardiomyocytes mature and exit the cell cycle during late prenatal and early postnatal life, there is a switch from proliferative to hypertrophic cellular growth (10) . Thus, beyond the neonatal period, growth of the heart is almost entirely reliant on hypertrophy of individual cardiomyocytes and the timing of this "switch" is of crucial importance. Apoptosis is known to be increased in the heart immediately postnatally (17) and may also be important in "fine-tuning" the cardiomyocyte pool to support ongoing myocardial growth. A reduction in the cardiomyocyte population in the neonate may render the heart more vulnerable later in life in situations where there is increased workload and/or stress (41) . How genetic disturbances in cardiomyocyte growth and viability early in development might predispose for adult pathologic hypertrophy has not been previously examined.
Cardiomyocyte growth responses mediated by G proteincoupled receptor (GPCR) signaling and mitogen-activated protein kinases (MAPKs) are well described (21) . Activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and/or p38 MAPK is a prominent feature of the response to pressure overload and hypertrophy induction in the adult heart (21). MAPK pathways have thus been characterized as mediating pathological remodeling in adult hearts, but they may also support physiological growth of the heart in some contexts (5) . Additionally, an insulin/insulin-like growth factor 1-responsive signaling pathway involving activation of phosphoinositide 3-kinase (PI3K) and Akt associated with physiological hyper-trophy of the heart has been delineated (35) . Despite intensive interrogation of these signaling pathways in the adult heart, an understanding of the contributions of MAPK vs. PI3K/Akt signaling in defining growth in the neonatal heart is lacking.
The central aim of this investigation was to determine how pathological hypertrophy in the adult can be linked with disturbances in cardiomyocyte growth and viability in early neonatal development. In this study, we experimentally investigate the developmental origins of primary cardiac hypertrophy in the hypertrophic heart rat (HHR), a genetic model derived from the SHR, which exhibits marked spontaneous cardiac hypertrophy at maturity in the absence of pressure loading (3, 20) . We hypothesized that heritable cardiac hypertrophy has origin in decreased cardiomyocyte viability and abnormal growth and trophic signaling in the neonate. Our investigation of growth phenotypes in the neonate and adult identifies novel molecular and cellular mechanisms involved in the etiology of inherited pathological cardiac hypertrophy.
METHODS

Experimental animals and tissue collection.
All experiments were conducted according to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (NHMRC/CSIRO/ACC, 1997) with the approval of the University of Melbourne Animal Experimentation Ethics Committee. The HHR, and its control strain the normal heart rat (NHR), were developed at the University of Melbourne, as previously described (20) . Longevity data were collected over a period of 16 mo. Rats were monitored throughout the 16-mo study for overt signs of congestive heart failure including lethargy, labored breathing, and cyanosis. At the time of death, hearts were fixed in 10% formalin, and transverse sections were stained with hematoxylin and eosin for histological analysis of chamber remodeling. Sections were imaged at ϫ0.4 magnification.
Hearts were excised from male NHR and HHR at postnatal day 2 (neonate) and at 4, 6, 8, 12 , and 20 wk of age. Neonates were killed by decapitation, while older rats were killed by overdose of halothane. After dissecting away noncardiac tissue, cardiac mass was recorded and normalized to body mass to give a cardiac weight index (CWI, mg/g). Atrial tissues were then removed from ventricles (septum intact), and ventricles were blotted and weighed before snap-freezing in liquid nitrogen for storage at Ϫ80°C.
Cardiomyocyte morphology. For cardiomyocyte morphological analyses, cells were obtained from neonatal (P2) and adult (12 wk) NHR and HHR ventricles by enzymatic digestion. Cardiomyocytes were isolated from 12-wk-old NHR/HHR hearts, as described previously (20) . Briefly, hearts were mounted onto a Langendorff column for retrograde perfusion with bicarbonate-buffered Krebs solution at 36°C, and ventricular myocytes were dissociated using collagenase (0.45 mg/ml) (20) . From each heart, 100 rod-shaped and regularly striated cardiomyocytes were selected at random for length and width measurement at ϫ400 magnification using an inverted light microscope and calibrated eye piece as previously described (13) .
Neonatal cardiomyocytes were isolated from 2-day-old NHR/HHR ventricles by enzymatic digestion with collagenase and trypsin as described previously (44) . The number of enzymatically isolated cardiomyocytes per heart was determined by hemocytometry from eight independent experiments for each strain (n ϭ 6 hearts per isolation). For cell length and width determination, 25 fields of isolated cardiomyocytes were imaged using a black and white 1300 ϫ 1300 pixel Coolsnap FX CCD camera (Roper Scientific) mounted on a Zeiss Axiovert 100M inverted microscope utilizing a Zeiss PlanNeofluar ϫ40 objective. Maximum cell length and width were calculated for a total of 79 NHR and 75 HHR rod-shaped cardiomyocytes using quantitative phase microscopy (QPM) image analysis software (ver. 2.0, Iatia, Box Hill North, VIC, Australia).
Nucleation. Freshly isolated neonatal cardiomyocytes were incubated for 30 min at room temperature with 70 M Hoechst 33342 (Sigma-Aldrich, St. Louis, MO) to label nuclei. Images were captured using a black and white 1300 ϫ 1300 pixel Coolsnap FX CCD camera (Roper Scientific, Tucson, AZ) mounted on a Zeiss Axiovert 100 M inverted epifluorescence microscope utilizing a Zeiss Plan-Neofluar ϫ40 objective. Images were analyzed using unbiased thresholding procedures, and the percentage of binucleated cells determined using QPM image analysis software (ver. 2.0, Iatia) from a sample of 10 fields of cells (ϳ100 cells per field) chosen at random from each cardiomyocyte preparation (n ϭ 6 hearts per strain).
Quantification of myocardial apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Cryosections (20 m) from the midventricle of postnatal day 2 NHR and HHR hearts were stained with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) to detect nuclear fragmentation using an apoptosis detection kit (in situ cell death detection kit, TMR Red, Roche, Australia) according to the manufacturer's instructions. Sections were also counterstained with 4Ј,6-diamidino-2-phenylindole-2 HCl (DAPI; Sigma-Aldrich) to label total nuclei. Eight to ten images per section were taken at ϫ10 magnification to cover the entire section and ensure that every nucleus was included in the analysis. Counting was restricted to the myocardium by exclusion of cells within a distance of 66 pixels (ϳ10 cell layers) from the edge of the tissue. The total area of DAPI-stained nuclei was calculated using Image Pro Plus v4.5.1 (Media Cybernetics, Silver Spring, MD) image analysis software. The sum of TUNEL-positive nuclei in the myocardium was divided by the total area of the 4,6-diamidino-2-phenylindole(DAPI)-stained nuclei per section to obtain an apoptotic index (TUNEL/DAPI).
Real-time PCR. Total RNA was extracted from ventricles using TriZOL Reagent (Invitrogen, Mount Waverly, VIC, Australia), according to the manufacturer's recommended protocol. The purity and integrity of the RNA sample were indicated by an A 260nm/A280nm ratio of 1.9 -2.1 and by the presence of two distinct bands, corresponding to the 28S and 18S ribosomal RNA subunits, following electrophoresis of RNA on a 1.2% agarose gel. Complementary DNA (cDNA) was synthesized from 4 g of total RNA using the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen), utilizing random hexamers as primer, according to the manufacturer's recommended protocol. cDNA was stored at Ϫ20°C until further use.
Real-time PCR was used to determine mRNA expression levels of ANP, BNP, ␤-MHC, p53, bax-1, and bcl-2 in ventricular tissues of HHR and NHR. 18S ribosomal RNA was used as a stably expressed housekeeping gene for all samples. Primers and probes for ANP, BNP, ␤-MHC, and 18S are as previously described (7, 42) . Sense and antisense primers for p53, bax-1, and bcl-2 were designed using Primer Express v1.5 (Applied Biosystems, Scoresby, VIC, Australia), with reference to known sequences in the rat (GenBank accession numbers are NM_030989, NM_017059 and NM_016993, respectively). p53 sense: 5ЈCATGAGCGTTGCTCTGATGGT3Ј; p53 antisense: 5ЈGATTTCCTTCCACCCGCATAAG3Ј; bax-1 sense: 5ЈGAGCT-GCAGAGGATGATTGCT3Ј; bax-1 antisense: 5ЈGCGGCCCCAGTT-GAAGT3Ј; bcl-2 sense: 5ЈTGGGATGCCTTTGTGGAACT3Ј; bcl-2 antisense: 5ЈAGACAGCCAGGAGAAATCAAACA3Ј; 18S sense: 5ЈTC-GAGGCCCTGTAATTGGAA3Ј, antisense: 5ЈCCCTCCAATGGATCC-TCGTT3Ј. p53, bax-1, and bcl-2 primers were produced by Gene Works (SA, Australia), while ANP, BNP, ␤-MHC, and 18S primers and probes were synthesized by Applied Biosystems.
mRNA expression levels were measured by real-time PCR using the Rotor-Gene 3000 (Corbett Research, NSW, Australia) and Taqman probe chemistry (for ANP, BNP, ␤-MHC) or SYBR green chemistry (Platinum SYBR qPCR Supermix UDG, Invitrogen). Each sample was run in triplicate and a final melt step (60 -99°C at a linear rate of 1°C/min) was carried out at the completion of the PCR reaction to monitor reaction specificity. Data obtained from real-time PCR reactions were analyzed using the sequence detector software (RotorGene ver. 6.0, Corbett Research). Expression of the gene of interest was normalized to 18S expression using the 2 Ϫ⌬⌬Ct method (32) or to a standard curve as appropriate.
Western immunoblot and kinase assay. Heart lysates were prepared and an in vitro PI3K assay (IRS1-associated) was carried out as previously described (3, 43) . Phosphorylation of Akt (Ser473), S6 (Ser235/236), ERK1/2 (Thr202/Tyr204), p38 MAPK (Thr180/ Tyr182) (1:1,000), and total expression levels of Akt, S6, ERK1/2, p38 MAPK, calcineurin A, and proliferating cell nuclear antigen (PCNA/Ki67) were assessed by Western blot analysis, as described previously (3) . Primary antibodies used included phospho-Akt (Ser473) (1:1,000), Akt (1:1,000), phospho-S6 (Ser235/236) (1:1,000), S6 (1:1,000), phospho-ERK1/2 (Thr202/Tyr204) (1:1,000), ERK1/2 (1:1,000), phospho-p38 MAPK (Thr180/Tyr182), p38 MAPK (1:1,000), calcineurin A (1:2,000), and PCNA (1:2,000). All antibodies were purchased from Cell Signaling (Beverly, MA).
Statistical analysis. All data are presented as means Ϯ SE. All multigroup comparisons were made using one-way or two-way ANOVA followed by Tukey's honestly significant difference test. Student's unpaired t-test was used for comparisons between the two groups. A value of P Ͻ 0.05 was considered significant.
RESULTS
Hypertrophic pathology in the adult HHR. Primary hypertrophy in the adult HHR was associated with premature mortality. Over a 16-mo longevity study (HHR: 50% survival), HHR exhibited increased mortality compared with NHR controls (Fig. 1A) . Post mortem analysis revealed that premature lethality in the HHR group was associated with a dilated cardiac phenotype (Fig. 1B) . Analysis of hearts from senescent rats (48 -64 wk) revealed that the cardiac weight index was ϳ51% higher in HHR compared with NHR at the time of death (5.9 Ϯ 0.6 vs. 3.9 Ϯ 0.1 mg/g). Before premature death, HHR displayed overt signs of congestive heart failure, including lethargy, labored breathing, and cyanosis. Cardiac hypertrophy in young adult HHR at 12 wk (Table 1 and Fig. 1D ) was associated with significant upregulation of the hypertrophic gene markers, BNP, ANP, and ␤-MHC (Fig. 1C) .
Ontogeny of cardiac hypertrophy in the HHR. In contrast, neonatal cardiac growth was reduced in HHR relative to NHR. At postnatal day 2, HHR hearts were considerably smaller than NHR, and cardiac weight normalized to body weight was also significantly reduced (Table 1 and Fig. 1D ). Isolated cardiomyocytes from neonatal HHR were significantly shorter and thinner than those from NHR (Table 1) .
Beyond the early postnatal period, HHR hearts exhibited significant "catch-up" growth. At 4 wk, HHR and NHR cardiac weight indices were similar (5.1 Ϯ 0.2 mg/g vs. 5.2 Ϯ 0.1 mg/g) and by 8 wk of age the HHR index was 11% larger than NHR. This was followed by a rapid period of growth, and by 12 wk of age, HHR cardiac weight index was 27% larger than NHR (P Ͻ 0.01, Fig. 1D ). Substantial hypertrophy was also evident at the cellular level, with HHR cardiomyocytes being significantly longer and wider than those from NHR at 12 wk of age (Table 1) .
Cardiomyocyte maturation. The number and nucleation status of isolated cardiomyocytes was determined in growthrestricted neonatal HHR hearts. On average, the number of cardiomyocytes isolated from neonatal HHR hearts was 29% less than the number isolated from age-matched NHR hearts (P ϭ 0.001, Fig. 2A ), suggesting that there are fewer Fig. 1 . Premature mortality, pathological adult hypertrophic remodeling, and neonatal heart growth abnormality in the hypertrophic heart rat (HHR). A: survival plot of normal heart rat (NHR) (dashed line) and HHR (solid line) over the 16-mo observational period. Survival is expressed as a percentage of total number of animals per group (n ϭ 10) surviving at observational time (in mo). B: transverse sections of hearts from nonsurviving NHR and HHR. A representative transverse section of a HHR exhibiting a dilated phenotype at 14 mo of age is shown. C: hypertrophic gene marker expression in NHR (n ϭ 5) and HHR (n ϭ 5) at 12 wk. BNP, ANP, and ␤-MHC mRNA expression levels (means Ϯ SE) presented as a fold change (relative to NHR) normalized to 18S. D: maturational heart growth in NHR and HHR. HHR cardiac weight index (mean Ϯ SE), expressed as a percentage difference relative to control NHR (set to 100%), at postnatal day 2 (neonate) and at 4, 6, 8, 12, and 20 wk of age. *P Ͻ 0.05. Student's unpaired t-test.
cardiomyocytes in the HHR heart at birth. The proportion of binucleated cardiomyocytes was markedly lower than that of mononucleated cardiomyocytes in the neonatal heart of both strains at postnatal day 2 (ϳ6% binucleated vs. 94% mononucleated), consistent with previous reports (30) . Neonatal HHR hearts contained a significantly higher percentage of binucleated cardiomyocytes compared with NHR (P ϭ 0.01, Fig. 2B) .
Myocardial proliferation and apoptosis. The possibility that a decrease in cardiomyocyte proliferation or an increase in apoptosis contributed to the reduction in cardiomyocyte number in the HHR neonatal heart was assessed. Cellular proliferation in the neonatal heart was assessed by Western immunoblot of nuclear extracts for the presence of the proliferating cell nuclear antigen (PCNA/Ki67). PCNA expression levels in NHR and HHR ventricles at postnatal day 2 were not significantly different (Fig. 2C) . In contrast, the apoptotic index (TUNEL-positive cells in myocardium normalized to total area of DAPI-stained nuclei) was suppressed by two-thirds in the neonatal HHR ventricle (Fig.  3A) . Gene expression levels of key apoptotic markers were also analyzed. HHR hearts exhibited significantly lower mRNA expression levels of the proapoptotic protein p53 (Fig. 3B) . No differences in bax-1, bcl-2, or the ratio of bax-1/bcl-2 mRNA were detected between NHR and HHR neonatal hearts (Fig. 3B and data not shown) .
PI3K/Akt signaling. The status of PI3K signaling in ventricular lysates from NHR and HHR neonatal hearts was assessed. The activity of IRS1-associated PI3K was 3.5-fold higher in HHR hearts at postnatal day 2 (Fig. 4A) . The ratio of phosphorylated (Ser473) to total Akt was also significantly increased in HHR neonatal hearts (P Ͻ 0.001, Fig. 4B ). Consistent with increased activity of Akt in HHR neonatal hearts, the ratio of phosphorylated S6 (Ser235/236) to total S6 was 1.7-fold higher in the HHR (P Ͻ 0.05, Fig. 4C ).
MAPK and calcineurin signaling. The ratios of phosphorylated (Thr202/Tyr204) to total ERK1/2 (P ϭ 0.01, Fig. 5A ) and phosphorylated (Thr180/Tyr182) to total p38 MAPK (P ϭ 0.01, Fig. 5B ) were reduced in HHR neonatal hearts. Calcineurin A levels were not different between NHR and HHR neonates (Fig. 5C ).
In adults (12 wk), IRS1-associated PI3K activity, p-Akt/Akt and p-S6/S6 did not differ between NHR and HHR (Fig. 6) . Additionally, in adult hearts (12 wk), no significant differences in p-ERK/ERK, p-P38/P38, or calcineurin A were detected between NHR and HHR (Fig. 7) .
DISCUSSION
This study is the first to demonstrate that heritable pathologic adult cardiac hypertrophy is preceded by cardiac growth suppression in early life. We show that cardiac growth restriction in the neonate, associated with abnormal cardiomyocyte maturation and accelerated transition to terminal differentiation, sets the stage for adult cardiac hypertrophy, cardiac failure, and premature mortality. We have previously reported that cardiac enlargement associated with cardiomyocyte hypertrophy in the adult is linked with myocyte reduction (20) . In the present study, we establish that this reduced cardiomyocyte endowment is evident in early development in the prehyper- trophic heart. Together, these findings indicate that when the neonate heart, characterized by smaller and fewer myocytes, undergoes maturation, there is an exaggerated degree of cellular hypertrophy, which produces an overall increase in heart size in the adult. We also observe that growth stress in the neonate is associated with accentuated PI3K and suppressed MAPK activation, although these signaling pathways are normalized in the adult heart exhibiting established hypertrophy. Thus, using the HHR model, novel molecular and cellular mechanisms involving premature exit from the cell cycle and dysregulated trophic signaling during early development are identified and implicated in the etiology of primary cardiac hypertrophy in the adult. The finding that pathological cardiac hypertrophy in adulthood can be traced to early cardiac growth suppression is unexpected and paradoxical. Our study reveals that there is a transition from a small heart to a large heart at about 4 wk of age in HHR. By 12 wk of age, there is clear structural and molecular evidence of hypertrophy. With a reduced cell population, increased loading of individual myocytes in the heart may constitute a stimulus for excessive cellular hypertrophy during maturation. Consistent with this hypothesis is the recent observation in survivin knockout mice that cardiomyocyte size in mature animals increased exponentially in association with a decrease in total myocyte number (27) . A reduction in cardiomyocyte number might occur through either increased cardiomyocyte loss or reduced cellular proliferation. We found that expression levels of the cell proliferation marker PCNA/ Ki67 were not different between NHR and HHR, suggesting that deficiency of proliferative signaling per se is not the cause for reduced cell numbers. Instead, it seems likely that the early period of physiological cardiomyocyte proliferation is abbreviated, as the cardiomyocytes from the small neonatal HHR show phenotypes that suggest inappropriate acceleration into terminal differentiation. In particular, the increased proportion of binucleated cardiomyocytes in the HHR neonatal heart suggests a premature exit from the proliferative cell cycle that may limit cell division and contribute to a reduction in cardiomyocyte number. Our preliminary data suggest that in the HHR, heart size is already reduced at embryonic day 18 (data not shown), suggesting that premature cell cycle exit most likely occurs before birth.
Interestingly, the SHR, from which the HHR is derived, also displays accelerated myocyte maturation and apoptotic suppression during the neonatal period (9, 15, 16, 36) . In contrast to the HHR, heart size in the SHR neonate is increased (29, 36) . Importantly, blood pressure is increased in the neonatal SHR, indicating that elevated pressure loading determines an Fig. 4 . Neonatal ventricular PI3K activity and phosphorylation of Akt and S6 in HHR. A: IRS1-associated PI3K activity (means Ϯ SE) in NHR (n ϭ 3) and HHR (n ϭ 4) presented as a fold-change (relative to NHR). A representative film depicting differential PI3K activity in HHR (H) and NHR (N) is shown. B: ratio of phosphorylated to total levels of Akt in NHR (n ϭ 6) and HHR (n ϭ 7) determined by Western blot quantification (cytosolic fractions). C: ratio of phosphorylated to total levels of S6 in NHR (n ϭ 6) and HHR (n ϭ 7) determined by Western blot quantification (cytosolic fractions). Phospho:total ratios presented as a fold change (means Ϯ SE) relative to NHR. Representative blots shown for NHR (N) and HHR (H) loaded in alternating lanes.*P Ͻ 0.05. Student's unpaired t-test. Fig. 3 . Incidence of myocardial apoptosis in NHR and HHR neonatal ventricles. A: apoptosis incidence in NHR (n ϭ 10) and HHR (n ϭ 10) neonatal ventricles (mid-ventricle). B and C: apoptotic gene marker expression in 2-day-old NHR (n ϭ 8) and HHR (n ϭ 10). p53 (B) and bax-1/bcl-2 (C) mRNA expression levels (means Ϯ SE) presented as fold change (relative to NHR) normalized to 18S. *P Ͻ 0.05. Student's unpaired t-test.
overall increase in heart size in the SHR at an early growth stage (2, 19) . Whether increased heart size in the SHR neonate is due to an increase in cardiomyocyte number is controversial. While Engelmann and Gerrity reported reduced rates of hyperplasia in SHR neonates during the first 5-8 postnatal days and suggested that SHR neonatal hearts contained fewer cardiomyocytes than their normotensive controls (15), findings of elevated DNA content (corrected for body weight) in SHR hearts at birth dispute this interpretation (9, 40) . However, using DNA content as a surrogate for measuring cardiomyocyte number could result in an overestimation of cell numbers in the SHR (relative to WKY) due to the increased proportion of binucleated cardiomyocytes in this strain (9) . It is possible that in the SHR, as in the HHR, there is an underlying genetically determined phenotype of reduced cell endowment, which in the absence of increased blood pressure, would confer reduced cardiac mass.
The observation of reduced cardiac growth in the HHR neonate may also relate to findings in rodent models of restricted maternal gestational protein intake or intrauterine growth restriction, where decreased fetal/neonatal cardiac growth is usually, but not always, observed (4, 23, 37, 38) . A significant reduction in total myocyte number or volume is observed in hearts from rats with intrauterine growth restriction (11), consistent with myocyte loss during early development. Cardiac enlargement is evident in older offspring of protein-restricted mothers (8) , a phenotype that may also be interpreted as an exaggerated maturational hypertrophic response. Collectively, these findings suggest that a reduced number of cardiomyocytes may render the heart more vulnerable to subsequent hypertrophy in response to the maturational loading increases associated with postnatal cardiac growth. Specifically, this study suggests that a genetically defective growth program in early development, even in the absence of maternal nutritional constraint, predisposes for later pathological cardiac hypertrophy.
We have made the novel observation that PI3K/Akt signaling is upregulated in the growth-restricted HHR neonatal heart. The suppressed myocardial apoptosis observed in the HHR neonate is consistent with increased PI3K/Akt activity (18) . Thus, it is feasible to speculate that PI3K/Akt-mediated suppression of apoptosis may represent a protective mechanism to preserve the already low numbers of cardiomyocytes in these animals. The tumor suppressor p53 plays a key role in the B: ratio of phosphorylated to total levels of Akt in NHR (n ϭ 10) and HHR (n ϭ 10) determined by Western blot quantification (cytosolic fractions). C: ratio of phosphorylated to total levels of S6 in NHR (n ϭ 10) and HHR (n ϭ 10) determined by Western blot quantification (cytosolic fractions). Phospho:total ratios presented as a fold change (mean Ϯ SE) relative to NHR. Representative blots shown for NHR (N) and HHR (H) loaded in alternating lanes.
induction of apoptosis (26) , and p53 was reduced in the HHR neonatal heart. Of particular interest, p38 MAPK-mediated apoptotic signaling involves phosphorylation and activation of p53 (6) . We speculate that the reciprocal regulation of p53 by enhanced PI3K/Akt signaling and reduced p38 MAPK signaling in the HHR neonatal heart provides the mechanism for suppression of apoptosis. Apoptotic suppression may act, in part, to preserve a reduced myocyte pool at birth, as cardiomyocytes begin to exit the cell cycle. However, given the generally low incidence of myocardial apoptosis (ϳ5-20 apoptotic cells/10,000 cells, Fig. 3A ) many more cells would be "lost" through premature differentiation (Fig. 2B ) than would be preserved by suppressed apoptosis, and the cell salvage effect of suppressed apoptosis may be limited.
The etiology of cardiac hypertrophy in the HHR is unusual in that it does not involve upregulation of classical signaling pathways associated with pathological remodeling in the adult (i.e., calcineurin and MAPKs). It is possible that MAPK pathway signaling is upregulated for some period of time after the growth restriction but before reaching an established level of hypertrophy. At 4 wk, HHR MAPK signaling is not different to NHR (data not shown), but the possibility of a transitory increase in MAPK signaling at other prehypertrophic time points cannot be excluded. Similarly, the involvement of key GPCR cardiac growth regulators (e.g., mediators of the reninangiotensin system) may be of importance in modeling the neonatal heart growth and predisposing for later hypertrophy.
An understanding of the contributions of MAPK vs. PI3K/ Akt signaling in defining growth in the normal neonatal heart and in neonatal hearts destined for adult hypertrophy is lacking. Upregulation of PI3K signaling is generally considered to be protective in the adult. Adult mice with reduced PI3K␣ signaling have significantly smaller hearts and an impaired hypertrophic response to physiological stimuli (e.g., swim training) (31, 43) . In the HHR setting, PI3K/Akt upregulation could be induced as a growth-promoting influence in the context of neonatal growth stress. While upregulation of PI3K/Akt signaling during the neonatal period might be initially beneficial in the HHR, hyperactivation of this signaling pathway appears to be ultimately associated with adverse cardiac remodeling, upregulation of pathological hypertrophic markers and heart failure at maturity. The notion that early compensation can drive later pathology is not without precedence. With adult onset pressure overload, the initial induction of cardiac hypertrophy is interpreted to comprise a compensatory response to normalize wall stress (14) . It could be speculated that heightened activation of cardiomyocyte growth signaling, regardless of the underlying stimulus, is detrimental to cardiac function in the setting of reduced cellular endowment. Future studies will be required to determine the efficacy of early clinical intervention to disrupt PI3K signaling in the neonate and reset the growth trajectory when neonatal cardiac growth is restricted. Interestingly, activation of PI3K in the heart has been linked with suppression of ERK signaling (34) , although the mechanisms for this "cross-talk" have not been delineated. We found reduced phosphorylation of both ERK1/2 and p38 MAPK in association with increased Akt activation in the HHR neonatal heart, supporting the notion of negative cross talk between these signaling pathways. The possibility that decreased MAPK activity may be a cause, rather than a consequence, of elevated PI3K signaling also requires consideration, and should also be a target for further investigation.
In summary, this study is the first to demonstrate that adult primary cardiac hypertrophy, unconfounded by hypertension, is associated with cardiac growth restriction at birth. Increased PI3K/Akt signaling and reduced MAPK signaling in the neonate precede the onset of hypertrophy in adulthood. At the cellular level, accelerated transition to terminal differentiation coincident with a reduction in the cardiomyocyte population in the neonate are observed. While future studies are required to elucidate the precise role of these early molecular and cellular alterations in the pathogenesis of hypertrophy, the present findings indicate that cardiac enlargement at maturity may be linked with perinatal cell growth and death signaling disturbance. An increased understanding of the determinants of appropriate physiological growth of the heart during early life may provide the basis for identifying early therapeutic inter- Fig. 7 . Phosphorylation of ERK1/2 and p38 MAPK and total levels of calcineurin A in 12-wk-old NHR and HHR ventricles. Ratios of phosphorylated to total levels of ERK1/2 (A) and p38 MAPK (B), and total levels of calcineurin A (C) in NHR (n ϭ 10) and HHR (n ϭ 10) ventricles at 12 wk of age determined by quantification of Western blots (cytosolic fractions). Phospho:total ratios presented as a fold change (means Ϯ SE) relative to NHR. Representative blots shown for NHR (N) and HHR (H) loaded in alternating lanes.
vention strategies for the prophylaxis of later onset cardiac hypertrophy.
